Initial Therapeutics is develops small-molecule medicines to prevent pathogenic protein synthesis. Their approach is different from protein degradation and other interventions that recognize and address proteins only after they are fully formed. Initial Therapeutics develops therapeutics for cancer and neurological disorders using proprietary technology to address high-confidence drug targets.

Initial Therapeutics

Director, Discovery Science

Ribosomes and ZAK protein spur the cell's initial response to UV radiation damage - News-Medical.Net

 Startup launched by 3 UC scientists, including husband of Nobel laureate Jennifer Doudna, hires CEO 

Ribosome Expert Rachel Green Selected to Direct Molecular Biology and Genetics Department at Johns Hopkins Medicine - Johns Hopkins Medicine


              Initial Therapeutics
            

We're #hiring a new Director, Discovery Science in South San Francisco, California. Apply today or share this post with your network.

'Undruggable is only at a given point in time': Prominent California scientists launch Initial Therapeutics with $75M - Endpoints News

We're #hiring a new Senior Scientist, Tumor Biology in South San Francisco, California. Apply today or share this post with your network.

Startup launched by 3 UC scientists, including husband of Nobel laureate Jennifer Doudna, hires CEO - The Business Journals


              NextGen Class of 2024: Top Life Sciences Startups to Watch This Year | BioSpace
            

 Initial Therapeutics Names Peter DiLaura as CEO 

 Research Institute Bio-Assay Development jobs in United States | by Relevance 

We're #hiring a new Principal Scientist, Tumor Biology & Biomarker Research in South San Francisco, California. Apply today or share this post with your network.

Excited to welcome our new CEO Peter DiLaura !

https://lnkd.in/eCb9Tr7j

 Articles about Initial Therapeutics 

Initial Therapeutics Names Peter DiLaura as CEO - PR Newswire

Initial Therapeutics

Business:

About: